vs
博士伦健康（BHC）与PILGRIMS PRIDE CORP（PPC）财务数据对比。点击上方公司名可切换其他公司
PILGRIMS PRIDE CORP的季度营收约是博士伦健康的1.6倍（$4.5B vs $2.8B），PILGRIMS PRIDE CORP净利率更高（2.2% vs -3.7%，领先5.9%），博士伦健康同比增速更快（9.3% vs 1.6%），过去两年博士伦健康的营收复合增速更高（14.0% vs -0.3%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
Pilgrim's Pride是美国跨国食品企业，为美国及波多黎各最大的鸡肉生产商之一，同时是墨西哥第二大鸡肉生产商。公司2009年12月脱离破产状态，2011年将美国总部迁至科罗拉多州格里利，由JBS集团控股，2016年11月底以3.5亿美元收购Gold'n Plump。
BHC vs PPC — 直观对比
营收规模更大
PPC
是对方的1.6倍
$2.8B
营收增速更快
BHC
高出7.7%
1.6%
净利率更高
PPC
高出5.9%
-3.7%
两年增速更快
BHC
近两年复合增速
-0.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $4.5B |
| 净利润 | $-103.0M | $101.5M |
| 毛利率 | — | 7.6% |
| 营业利润率 | 17.0% | 3.6% |
| 净利率 | -3.7% | 2.2% |
| 营收同比 | 9.3% | 1.6% |
| 净利润同比 | -205.1% | — |
| 每股收益（稀释后） | $-0.30 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCPPC
| Q1 26 | — | $4.5B | ||
| Q4 25 | $2.8B | $4.5B | ||
| Q3 25 | $2.7B | $4.8B | ||
| Q2 25 | $2.5B | $4.8B | ||
| Q1 25 | $2.3B | $4.5B | ||
| Q4 24 | $2.6B | $4.4B | ||
| Q3 24 | $2.5B | $4.6B | ||
| Q2 24 | $2.4B | $4.6B |
净利润BHCPPC
| Q1 26 | — | $101.5M | ||
| Q4 25 | $-103.0M | $88.0M | ||
| Q3 25 | $179.0M | $342.8M | ||
| Q2 25 | $148.0M | $355.5M | ||
| Q1 25 | $-58.0M | $296.0M | ||
| Q4 24 | $98.0M | $235.9M | ||
| Q3 24 | $-85.0M | $349.9M | ||
| Q2 24 | $10.0M | $326.3M |
毛利率BHCPPC
| Q1 26 | — | 7.6% | ||
| Q4 25 | — | 9.5% | ||
| Q3 25 | — | 13.9% | ||
| Q2 25 | — | 15.0% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | — | 14.9% | ||
| Q2 24 | — | 15.2% |
营业利润率BHCPPC
| Q1 26 | — | 3.6% | ||
| Q4 25 | 17.0% | 4.5% | ||
| Q3 25 | 23.1% | 10.4% | ||
| Q2 25 | 17.5% | 10.8% | ||
| Q1 25 | 12.2% | 9.1% | ||
| Q4 24 | 21.8% | 7.0% | ||
| Q3 24 | 12.7% | 11.1% | ||
| Q2 24 | 16.2% | 9.7% |
净利率BHCPPC
| Q1 26 | — | 2.2% | ||
| Q4 25 | -3.7% | 1.9% | ||
| Q3 25 | 6.7% | 7.2% | ||
| Q2 25 | 5.8% | 7.5% | ||
| Q1 25 | -2.6% | 6.6% | ||
| Q4 24 | 3.8% | 5.4% | ||
| Q3 24 | -3.4% | 7.6% | ||
| Q2 24 | 0.4% | 7.2% |
每股收益（稀释后）BHCPPC
| Q1 26 | — | $0.43 | ||
| Q4 25 | $-0.30 | $0.37 | ||
| Q3 25 | $0.48 | $1.44 | ||
| Q2 25 | $0.40 | $1.49 | ||
| Q1 25 | $-0.16 | $1.24 | ||
| Q4 24 | $0.24 | $1.00 | ||
| Q3 24 | $-0.23 | $1.47 | ||
| Q2 24 | $0.03 | $1.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $542.4M |
| 总债务越低越好 | $20.8B | $3.1B |
| 股东权益账面价值 | $-554.0M | $3.7B |
| 总资产 | $26.4B | $10.2B |
| 负债/权益比越低杠杆越低 | — | 0.83× |
8季度趋势，按日历期对齐
现金及短期投资BHCPPC
| Q1 26 | — | $542.4M | ||
| Q4 25 | $1.3B | $640.2M | ||
| Q3 25 | $1.3B | $612.6M | ||
| Q2 25 | $1.7B | $849.0M | ||
| Q1 25 | $1.1B | $2.1B | ||
| Q4 24 | $1.2B | $2.0B | ||
| Q3 24 | $719.0M | $1.9B | ||
| Q2 24 | $595.0M | $1.3B |
总债务BHCPPC
| Q1 26 | — | $3.1B | ||
| Q4 25 | $20.8B | $3.1B | ||
| Q3 25 | $21.0B | $3.1B | ||
| Q2 25 | $21.7B | $3.1B | ||
| Q1 25 | $21.5B | $3.2B | ||
| Q4 24 | $21.6B | $3.2B | ||
| Q3 24 | $21.5B | $3.2B | ||
| Q2 24 | $21.7B | $3.2B |
股东权益BHCPPC
| Q1 26 | — | $3.7B | ||
| Q4 25 | $-554.0M | $3.7B | ||
| Q3 25 | $-565.0M | $3.5B | ||
| Q2 25 | $-764.0M | $3.7B | ||
| Q1 25 | $-1.2B | $3.1B | ||
| Q4 24 | $-1.3B | $4.2B | ||
| Q3 24 | $-1.2B | $4.2B | ||
| Q2 24 | $-1.2B | $3.7B |
总资产BHCPPC
| Q1 26 | — | $10.2B | ||
| Q4 25 | $26.4B | $10.3B | ||
| Q3 25 | $26.8B | $10.0B | ||
| Q2 25 | $27.3B | $10.1B | ||
| Q1 25 | $26.4B | $11.0B | ||
| Q4 24 | $26.5B | $10.7B | ||
| Q3 24 | $26.5B | $10.7B | ||
| Q2 24 | $26.5B | $10.1B |
负债/权益比BHCPPC
| Q1 26 | — | 0.83× | ||
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.85× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | — |
| 自由现金流经营现金流 - 资本支出 | $403.0M | — |
| 自由现金流率自由现金流/营收 | 14.4% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流BHCPPC
| Q1 26 | — | — | ||
| Q4 25 | $495.0M | $291.2M | ||
| Q3 25 | $405.0M | $458.3M | ||
| Q2 25 | $289.0M | $495.2M | ||
| Q1 25 | $211.0M | $126.9M | ||
| Q4 24 | $601.0M | $349.3M | ||
| Q3 24 | $405.0M | $651.1M | ||
| Q2 24 | $380.0M | $718.6M |
自由现金流BHCPPC
| Q1 26 | — | — | ||
| Q4 25 | $403.0M | $10.0M | ||
| Q3 25 | $314.0M | $275.9M | ||
| Q2 25 | $190.0M | $339.1M | ||
| Q1 25 | $96.0M | $28.1M | ||
| Q4 24 | $495.0M | $176.6M | ||
| Q3 24 | $334.0M | $565.3M | ||
| Q2 24 | $302.0M | $617.7M |
自由现金流率BHCPPC
| Q1 26 | — | — | ||
| Q4 25 | 14.4% | 0.2% | ||
| Q3 25 | 11.7% | 5.8% | ||
| Q2 25 | 7.5% | 7.1% | ||
| Q1 25 | 4.2% | 0.6% | ||
| Q4 24 | 19.3% | 4.0% | ||
| Q3 24 | 13.3% | 12.3% | ||
| Q2 24 | 12.6% | 13.5% |
资本支出强度BHCPPC
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 6.2% | ||
| Q3 25 | 3.4% | 3.8% | ||
| Q2 25 | 3.9% | 3.3% | ||
| Q1 25 | 5.1% | 2.2% | ||
| Q4 24 | 4.1% | 4.0% | ||
| Q3 24 | 2.8% | 1.9% | ||
| Q2 24 | 3.2% | 2.2% |
现金转化率BHCPPC
| Q1 26 | — | — | ||
| Q4 25 | — | 3.31× | ||
| Q3 25 | 2.26× | 1.34× | ||
| Q2 25 | 1.95× | 1.39× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | 6.13× | 1.48× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | 38.00× | 2.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
PPC
| U.S | $2.6B | 58% |
| Europe | $1.4B | 30% |
| Mexico | $545.5M | 12% |
